- NEWS FEATURE
Long-COVID treatments: why the world is still waiting
Illustration by Erick M. Ramos
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 608, 258-260 (2022)
doi: https://doi.org/10.1038/d41586-022-02140-w
References
Davis, H. E. et al. eClinicalMedicine 38, 101019 (2021).
Pretorius, E. et al. Cardiovasc. Diabetol. 20, 172 (2021).
Pretorius, E. et al. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-1205453/v1 (2021).
Ayoubkhani, D. et al. BMJ 377, e069676 (2022).
Imai, K. et al. Viruses 14, 907 (2022).
How common is long COVID? Why studies give different answers
Can drugs reduce the risk of long COVID? What scientists know so far
The four most urgent questions about long COVID